Findings of a Study With a Novel Antibody-Drug Conjugate in Ovarian Cancer

Updated progression-free survival analysis data presented at the 2023 ASCO Annual Meeting favored the combination of nivolumab plus relatlimab in patients with melanoma.

In season 2, episode 6 of Targeted Talks, Alexander B. Olawaiye, MD leads a discussion with Haider S. Mahdi, MD, about the modern approaches to treating cervical and endometrial cancers.

While the phase 2 CTEP-P9466 trial met its complete response end point, the trial missed its other co-primary end points in patients with BRAF V600–mutant metastatic melanoma.

Sarah M. Temkin, MD leads discussion with Daphne B. Stewart, MD, around targeted therapies in ovarian cancer, whether offered in the academic or community setting.

Epcoritamab plus rituximab/lenalidomide demonstrated antitumor activity in patients with relapsed/refractory follicular lymphoma, including those with high-risk features.

Treatment with lisocabtagene maraleucel elicited encouraging responses and met the primary end point of the TRANSCEND CLL 004 trial in patients with relapsed/refractory CLL/SLL.